

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CLARITY MEDICAL GROUP HOLDING LIMITED

清晰醫療集團控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1406)

- (1) RESIGNATION OF NON-EXECUTIVE DIRECTOR;**
- (2) APPOINTMENT OF EXECUTIVE DIRECTOR AND
CHIEF EXECUTIVE OFFICER;**
- (3) RE-DESIGNATION OF CO-CHIEF EXECUTIVE OFFICER;**
- (4) CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR;**
- AND**
- (5) CHANGE IN COMPOSITION OF BOARD COMMITTEES**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Clarity Medical Group Holding Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces the following changes to the composition of the Board with effect from 9 September 2024:

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The Board announces that Mr. Ng Roy (“**Mr. Ng**”) has tendered his resignation as a non-executive Director of the Company with effect from 9 September 2024 in order to devote more time on his other personal and business endeavours. Following his resignation, Mr. Ng has been appointed as a consultant of the Company with effect from 9 September 2024 for a period of two years.

Mr. Ng has confirmed that there is no disagreement with the Board and that he is not aware of any matter that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in relation to his resignation.

Mr. Ng was responsible for advising on the overall strategic planning of the Group during his tenure as a non-executive Director. The Board believes that the Company shall continue to benefit from his new role as consultant in advising on the Group's overall strategic planning. The engagement of Mr. Ng as a consultant constitutes a connected transaction of the Company under Chapter 14A of the Listing Rules. Nevertheless, it is fully exempt from all disclosure requirements pursuant to Rule 14A.76(1) of the Listing Rules.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Ng for his valuable contribution to the Company during his tenure of office as the non-executive Director and for taking up the new position as consultant.

APPOINTMENT OF EXECUTIVE DIRECTOR AND CHIEF EXECUTIVE OFFICER

The Board is pleased to announce that Mr. Jiang Bo (“**Mr. Jiang**”) has been appointed as an executive Director and Chief Executive Officer (the “**CEO**”) of the Company with effect from 9 September 2024. Mr. Jiang is responsible for the general management and business strategy formulation of the Group pursuant to his role as a CEO.

The biographical details of Mr. Jiang are set out below:

Mr. Jiang, aged 43, brings nearly twenty years of experiences in senior investment and operating positions at several renowned institutions. From October 2021 to June 2023, he was a partner at Index Capital, a leading fully integrated investment bank in China. Prior to that, Mr. Jiang was appointed as a non-executive director of Cosmo Lady (China) Holdings Company Limited (都市麗人(中國)控股有限公司), a company whose shares are listed on the Stock Exchange (stock code: 2298), between May 2020 and February 2022. From May 2018 to September 2021, Mr. Jiang led Fosun Private Equity (復星美元產業基金) as President, overseeing its investment and management activities. He was also appointed as a director of Beijing Airdoc Technology Co., Ltd (北京鷹瞳科技發展股份有限公司), a company whose shares are listed on the Stock Exchange (stock code: 2251), in December 2019, then was re-designated as non-executive director from April 2021 to May 2022. Earlier, he was a partner at Long Hill Capital from January 2017 to April 2018, where he specialized in healthcare and consumer services investments. His experience also includes a tenure as an executive director at New Enterprise Associates (NEA) from March 2012 to January 2017. Before that, Mr. Jiang served as a product director of the mobile business department of Alipay.com Co., Ltd (支付寶(中國)網路技術有限公司), which was an indirectly wholly-owned subsidiary of Alibaba Group Holding Limited (阿里巴巴集團控股有限公司), a company whose shares are listed on the New York Stock Exchange (ticker symbol: BABA) and the Stock Exchange (stock code: 9988), where he founded the mobile payment team and led the development and launch of the first mobile payment product in China, between December 2006 and July 2010.

Mr. Jiang earned his Master of Business Administration from The Wharton School at the University of Pennsylvania in the United States in May 2012. Prior to this, he completed a Master of Philosophy in Industrial Engineering and Engineering Management at the Hong Kong University of Science and Technology in November 2005. He received his Bachelor's degree in Computer Science and Technology from Tsinghua University in the People's Republic of China, in July 2002.

Pursuant to the service agreement entered into between the Company and Mr. Jiang, Mr. Jiang is appointed as an executive Director for an initial term of three years commencing from 9 September 2024. His term as CEO will also be for three years. The term of service of Mr. Jiang as an executive Director is subject to retirement by rotation in accordance with the articles of association of the Company (the “**Articles**”) and the Rules Governing the Listing of Securities on the Stock Exchange (the “**Listing Rules**”). Mr. Jiang is entitled to an aggregate annual remuneration of HK\$960,000 for his roles as executive Director and CEO, which was recommended by the remuneration committee of the Company (the “**Remuneration Committee**”) and determined by the Board, with reference to his responsibilities, experience and market rate of directors' remuneration of listed companies of a comparable size of operation.

Save as disclosed above, Mr. Jiang (i) did not hold any other directorship in other listed companies during the past three years; (ii) does not hold any position of the Company or any of its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under Listing Rules) of the Company; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”) as at the date of this announcement.

Save as disclosed above, neither is there any further information required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules, nor is there any other matter relating to the appointment of Mr. Jiang that needs to be brought to the attention of the shareholders of the Company.

The Company would like to express its warmest welcome to Mr. Jiang in joining the Board.

RE-DESIGNATION OF CO-CHIEF EXECUTIVE OFFICER

Following the appointment of Mr. Jiang as a CEO, Mr. Hui Yung Chris (“**Mr. Hui**”), an executive Director and the Chief Executive Officer of the Company, has been re-designated as a Co-CEO with effect from 9 September 2024. His position as an executive Director remains unchanged. Mr. Hui will focus on managing and overseeing the Group's ophthalmic services and business development in the Greater Bay Area pursuant to his role as a Co-CEO.

The biographical details of Mr. Hui are set out below:

Mr. Hui, aged 55, was appointed as an independent non-executive Director on 29 March 2019 and he was also a member of the audit committee of the Company (the “**Audit Committee**”) and the Remuneration Committee. He was responsible for supervising and providing independent advice to our Board during his tenure as an independent non-executive Director. Mr. Hui has been re-designated from an independent non-executive Director to an executive Director and ceased to act as a member of each of the Audit Committee and the Remuneration Committee on 30 June 2022 and he was also appointed as the Chief Executive Officer with effect from 30 June 2022. He is currently responsible for overseeing overall business and development and operations of our Group. Mr. Hui obtained a bachelor’s degree in Business Administration from the Chinese University of Hong Kong in July 1991.

Mr. Hui has more than 25 years of experience in investment and capital markets and joined the Group since 29 March 2019. He currently also serves as an external supervisor for China Bohai Bank Co., Ltd., a company listed on the Main Board of the Stock Exchange (stock code: 9668) since December 2019. He served as the secretary of the board of directors of Wanda Commercial Properties Company Limited (“**WCP**”) (萬達商業地產股份有限公司) from September 2015 to February 2019. He also served as a non-executive director of Wanda Hotel Development Company Limited (萬達酒店發展有限公司), which is a subsidiary of WCP and is listed on the Main Board of the Stock Exchange (stock code: 169), from November 2017 to February 2019. Prior to joining WCP, Mr. Hui served as a founding partner of J&Partners GP Limited from December 2011 to September 2015. From July 2001 to July 2010, he worked at Barclays Investment Bank where he served as a managing director of Investment Banking Division. He also served as a director of New China Trust Co., Ltd. (新華信託股份有限公司) from November 2009 to October 2010, a director of Deutsche Bank in Asia Pacific from March 1996 to July 2001, and a vice president of the Debt Markets of Merrill Lynch (Asia Pacific) Limited from May 1994 to February 1996. Mr. Hui is also a director of various subsidiaries of the Company.

Pursuant to the service agreement entered into between the Company and Mr. Hui, Mr. Hui was appointed as an executive Director for an initial term of one year commencing on 30 June 2022. The term of service of Mr. Hui is subject to retirement by rotation in accordance with the Articles and the Listing Rules. Mr. Hui is entitled to an annual remuneration of HK\$3,600,000 for his role as Co-CEO, which was recommended by the Remuneration Committee and determined by the Board, with reference to his responsibilities, experience and market rate of executives’ remuneration of listed companies of a comparable size of operation. Mr. Hui shall not be entitled to any further remuneration in his capacity as an executive Director.

As at the date of this announcement, Mr. Hui is interested in 5,000,000 underlying shares of the Company in respect of the share awards granted by the Company within the meaning of Part XV of the SFO. Save as disclosed above, Mr. Hui (i) did not hold any other directorship in other listed companies during the past three years; (ii) does not hold any other position of the Company or any of its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under Listing Rules) of the Company; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the SFO as at the date of this announcement.

Save as disclosed above, neither is there any further information required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules, nor is there any other matter relating to the re-designation of Mr. Hui as the Co-CEO that needs to be brought to the attention of the shareholders of the Company.

CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The Board announces that Mr. Ma Wai Hung Vincent (“**Mr. Ma**”) has tendered his resignation as an independent non-executive Director of the Company with effect from 9 September 2024 in order to devote more time on his other personal and business endeavours.

Mr. Ma has confirmed that there is no disagreement with the Board and that he is not aware of any matter that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange in relation to his resignation.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Ma for his valuable contribution to the Company during his tenure of office as the independent non-executive Director.

The Board is pleased to announce that Mr. Wang Can (“**Mr. Wang**”) has been appointed as an independent non-executive Director of the Company with effect from 9 September 2024.

The biographical details of Mr. Wang are set out below:

Mr. Wang, aged 45, has been appointed as independent non-executive Directors of Atour Lifestyle Holdings Ltd. (listed on NASDAQ with stock code ATAT) with effect from November 2022. Mr. Wang served as the Chief Financial Officer of New Hope Group Co. Ltd and the Chairman of New Hope Finance Co. Ltd from September 2022 to July 2024. He was also an independent non-executive Director of Health and Happiness (H&H) International Holdings Limited (listed on the Stock Exchange with stock code 1112) from March 2020 to December 2022. Mr. Wang worked in the group of companies comprising Fosun International Limited (listed on the Stock Exchange with stock code 0656) (“**Fosun International**”) and its subsidiaries from time to time (the “**Fosun Group**”) from November 2012 to January 2020. Mr. Wang once worked as the Chief Growth

Officer (CGO), the Chief Financial Officer (CFO) of the Fosun Group. He was an executive director and senior vice president of Fosun International from March 2017 to January 2020, a non-executive director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (listed on the Stock Exchange with stock code 02196 and the Shanghai Stock Exchange with stock code 600196) from June 2016 to January 2020, a non-executive director of Fosun Tourism Group (listed on the Stock Exchange with stock exchange 01992) from November 2018 to January 2020, and a director of Shanghai Ganglian E-commerce Holdings Co., Ltd. (listed on the Shenzhen Stock Exchange with stock code 300226) from May 2017 to 3 October 2019. Prior to joining the Fosun Group, Mr. Wang worked in Kingdee Software (China) Co., Ltd., PricewaterhouseCoopers Zhong Tian LLP, Standard Chartered Bank (China) Limited and Huazhu Group Limited (listed on NASDAQ with stock code HTHT and the Stock Exchange with stock code 01179).

Mr. Wang is a non-practicing member of the Chinese Institute of Certified Public Accountants and a fellow member of the Association of Chartered Certified Accountants, and has been appointed as Deputy President of China Association of Chief Financial Officers since April 2021. Mr. Wang graduated from Anhui University in 1997 and received an EMBA degree from China Europe International Business School in 2014.

Pursuant to the letter of appointment entered into between the Company and Mr. Wang, Mr. Wang is appointed as an independent non-executive Director for an initial term of three years commencing from 9 September 2024. The term of service of Mr. Wang is subject to retirement by rotation in accordance with the Articles and the Listing Rules. Mr. Wang is entitled to receive a fixed director's remuneration of HK\$300,000 per annum, which was recommended by the Remuneration Committee and determined by the Board, with reference to his responsibilities, experience and market rate of directors' remuneration of listed companies of a comparable size of operation.

Save as disclosed above, Mr. Wang (i) did not hold any other directorship in other listed companies during the past three years; (ii) does not hold any position of the Company or any of its subsidiaries; (iii) does not have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under Listing Rules) of the Company; and (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the SFO as at the date of this announcement.

Save as disclosed above, neither is there any further information required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to (v) of the Listing Rules, nor is there any other matter relating to the appointment of Mr. Wang that needs to be brought to the attention of the shareholders of the Company.

Mr. Wang has confirmed that he has met the independence criteria set out in Rule 3.13 of the Listing Rules.

The Company would like to express its warmest welcome to Mr. Wang in joining the Board.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

Following Mr. Ng's resignation as a non-executive Director, he has also resigned as a member of the Remuneration Committee with effect from 9 September 2024.

Following Mr. Ma's resignation as an independent non-executive Director, he has also resigned as the chairman of the Remuneration Committee, and a member of each of the Audit Committee and the nomination committee of the Company (the "**Nomination Committee**") with effect from 9 September 2024.

Mr. Wang has been appointed by the Board as the chairman of the Remuneration Committee, and a member of each of the Audit Committee and the Nomination Committee with effect from 9 September 2024.

Mr. Jiang has been appointed by the Board as a member of the Remuneration Committee with effect from 9 September 2024.

By order of the Board
CLARITY MEDICAL GROUP HOLDING LIMITED
WU Ting Yuk Anthony
Non-Executive Director and Chairman

Hong Kong, 9 September 2024

As at the date of this announcement, the Board comprises Mr. HUI Yung Chris, Dr. TSE Wai Ip, Mr. LO Tsz Hong and Mr. JIANG Bo as executive Directors, Mr. WU Ting Yuk Anthony as Chairman and non-executive Director, Ms. ZHAO Wei as non-executive Director, Mr. LI Michael Hankin, Ms. CHENG Jessica and Mr. WANG Can as independent non-executive Directors.